Samuel C. Okpechi

550 total citations
19 papers, 358 citations indexed

About

Samuel C. Okpechi is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Samuel C. Okpechi has authored 19 papers receiving a total of 358 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Pulmonary and Respiratory Medicine, 6 papers in Oncology and 5 papers in Molecular Biology. Recurrent topics in Samuel C. Okpechi's work include Cancer, Lipids, and Metabolism (3 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (3 papers) and Pulmonary Hypertension Research and Treatments (3 papers). Samuel C. Okpechi is often cited by papers focused on Cancer, Lipids, and Metabolism (3 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (3 papers) and Pulmonary Hypertension Research and Treatments (3 papers). Samuel C. Okpechi collaborates with scholars based in United States, Egypt and India. Samuel C. Okpechi's co-authors include Suresh K. Alahari, Hassan Yousefi, Ladan Mashouri, Daniel F. Sarpong, Mohamed A. Ghonim, A. Hamid Boulares, Dorota Wyczechowska, Matthew R. Lammi, Salomè V. Ibba and Paulo C. Rodrı́guez and has published in prestigious journals such as Oncogene, The FASEB Journal and International Journal of Molecular Sciences.

In The Last Decade

Samuel C. Okpechi

19 papers receiving 350 citations

Peers

Countries citing papers authored by Samuel C. Okpechi

Since Specialization

Citations

This map shows the geographic impact of Samuel C. Okpechi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Samuel C. Okpechi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Samuel C. Okpechi more than expected).

Fields of papers citing papers by Samuel C. Okpechi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Samuel C. Okpechi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Samuel C. Okpechi. The network helps show where Samuel C. Okpechi may publish in the future.

Co-authorship network of co-authors of Samuel C. Okpechi

This figure shows the co-authorship network connecting the top 25 collaborators of Samuel C. Okpechi. A scholar is included among the top collaborators of Samuel C. Okpechi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Samuel C. Okpechi. Samuel C. Okpechi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work	Indexed citations
1	CDK2 inhibition produces a persistent population of polyploid cancer cells 2025 ·JCI Insight ·Liliya Tyutyunyk‐Massey, Zibo Chen, (unknown), Masanori Kawakami, Adam Harned, Yeap Ng, Brian T. Luke, Samuel C. Okpechi, (unknown), (unknown), Roberto Weigert, Kedar Narayan, Xi Liu, Ethan Dmitrovsky	1
2	Glycemic control in diabetic patients improved overall lung cancer survival across diverse populations 2024 ·JNCI Cancer Spectrum ·Yu‐Hung Wu, Brian T. Luke, (unknown), J. Jack Lee, (unknown), Samuel C. Okpechi, Barry L. Gause, Paras Mehta, Steven I. Sherman, Augusto C. Ochoa, (unknown), Xi Liu	3
3	A combination of novel NSC small molecule inhibitor along with doxorubicin inhibits proliferation of triple-negative breast cancer through metabolic reprogramming 2022 ·Oncogene ·Hassan Yousefi, (unknown), (unknown), Samuel C. Okpechi, David K. Worthylake, Jone Garai, Jovanny Zabaleta, Jessie J. Guidry, (unknown), Dorota Wyczechowska, Janarthanan Jayawickramarajah, Qinglin Yang, Joseph L. Kissil, Suresh K. Alahari	8
4	Role of Nischarin in the pathology of diseases: a special emphasis on breast cancer 2022 ·Oncogene ·Samuel C. Okpechi, Hassan Yousefi, Khoa Nguyen, Thomas Cheng, (unknown), Bridgette M. Collins‐Burow, Matthew E. Burow, Suresh K. Alahari	10
5	Ceritinib is a novel triple negative breast cancer therapeutic agent 2022 ·Molecular Cancer ·Shengli Dong, Hassan Yousefi, (unknown), Samuel C. Okpechi, (unknown), Margarite D. Matossian, Bridgette M. Collins‐Burow, Matthew E. Burow, Suresh K. Alahari	22
6	Nischarin Deletion Reduces Oxidative Metabolism and Overall ATP: A Study Using a Novel NISCHΔ5-6 Knockout Mouse Model 2022 ·International Journal of Molecular Sciences ·(unknown), Hassan Yousefi, Samuel C. Okpechi, (unknown), Shengli Dong, Qinglin Yang, Suresh K. Alahari	1
7	Global Sex Disparity of COVID-19: A Descriptive Review of Sex Hormones and Consideration for the Potential Therapeutic Use of Hormone Replacement Therapy in Older Adults 2021 ·Aging and Disease ·Samuel C. Okpechi, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Suresh K. Alahari	14
8	SPDEF targets EMT pathway to inhibit cell migration and invasion in triple‐negative breast cancer 2021 ·The FASEB Journal ·Hassan Yousefi, (unknown), Sweaty Koul, Samuel C. Okpechi, Suresh K. Alahari, Hari K. Koul	3
9	Association of Serum Magnesium with Blood Pressure in Patients with Hypertensive Crises: A Retrospective Cross-Sectional Study 2021 ·Nutrients ·(unknown), (unknown), (unknown), (unknown), (unknown), Robbie A. Beyl, (unknown), (unknown), (unknown), (unknown), Daniel F. Sarpong, (unknown), Samuel C. Okpechi, (unknown), (unknown), (unknown)	3
10	Acute effect of inhaled iloprost on exercise dynamic hyperinflation in COPD patients: A randomized crossover study 2021 ·Respiratory Medicine ·Matthew R. Lammi, Mohamed A. Ghonim, Jessica L. Johnson, (unknown), (unknown), (unknown), Samuel C. Okpechi, (unknown), (unknown), (unknown), Judd E. Shellito, A. Hamid Boulares, Bennett P. deBoisblanc	2
11	Repurposing existing drugs for the treatment of COVID-19/SARS-CoV-2 infection: A review describing drug mechanisms of action 2020 ·Biochemical Pharmacology ·Hassan Yousefi, Ladan Mashouri, Samuel C. Okpechi, (unknown), Suresh K. Alahari	79
12	Microparticles in systemic sclerosis: Potential pro‐inflammatory mediators and pulmonary hypertension biomarkers 2019 ·Respirology ·Matthew R. Lammi, Lesley Ann Saketkoo, Samuel C. Okpechi, Mohamed A. Ghonim, Dorota Wyczechowska, Natalie Bauer, (unknown), (unknown), Bennett P. deBoisblanc, A. Hamid Boulares	15
13	Pioglitazone’s beneficial effects on erectile function preservation after cavernosal nerve injury in the rat are negated by inhibition of the insulin-like growth factor-1 receptor: a preclinical study 2018 ·International Journal of Impotence Research ·(unknown), Nora M. Haney, Bashir M. Rezk, Sudha Talwar, Samuel C. Okpechi, Sudesh Srivastav, (unknown), Bryant M. Song, (unknown), (unknown), James Anaissie, Taylor Peak, Kenneth J. DeLay, P. J. Kadowitz, Suresh C. Sikka, Asim B. Abdel‐Mageed, Wayne J.G. Hellstrom	6
14	Fuelling the mechanisms of asthma: Increased fatty acid oxidation in inflammatory immune cells may represent a novel therapeutic target 2017 ·Clinical & Experimental Allergy ·Amir A. Al-Khami, Mohamed A. Ghonim, Luis Del Valle, Salomè V. Ibba, Luyao Zheng, (unknown), Samuel C. Okpechi, Jone Garay, Dorota Wyczechowska, (unknown), Paulo C. Rodrı́guez, A. Hamid Boulares, Augusto C. Ochoa	30
15	Advances in Chronic Obstructive Pulmonary Disease Therapy: A Vascular-Targeted Approach 2017 ·Samuel C. Okpechi, Mohamed A. Ghonim, Matthew R. Lammi	2
16	Clinical Effects of Cigarette Smoking: Epidemiologic Impact and Review of Pharmacotherapy Options 2017 ·International Journal of Environmental Research and Public Health ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Samuel C. Okpechi, Daniel F. Sarpong	111
17	ApoE deficiency promotes colon inflammation and enhances the inflammatory potential of oxidized-LDL and TNF-α in primary colon epithelial cells 2016 ·Bioscience Reports ·Ali H. El‐Bahrawy, (unknown), Hogyoung Kim, Venkat Subramaniam, (unknown), (unknown), Samuel C. Okpechi, Mohamed A. Ghonim, Ramadan A.M. Hemeida, Amira M. Abo‐Youssef, (unknown), Ihab T. Abdel‐Raheem, Jong Kim, Amarjit S. Naura, A. Hamid Boulares	7
18	Treatment with intranasal iloprost reduces disease manifestations in a murine model of previously established COPD 2016 ·American Journal of Physiology-Lung Cellular and Molecular Physiology ·Matthew R. Lammi, Mohamed A. Ghonim, (unknown), Amarjit S. Naura, Salomè V. Ibba, (unknown), Samuel C. Okpechi, Kyle I. Happel, Bennett P. deBoisblanc, Judd E. Shellito, A. Hamid Boulares	8
19	PARP is activated in human asthma and its inhibition by olaparib blocks house dust mite-induced disease in mice 2015 ·Clinical Science ·Mohamed A. Ghonim, (unknown), Salomè V. Ibba, Jeffrey Wang, Paulo C. Rodrı́guez, Amir A. Al-Khami, Matthew R. Lammi, Hogyoung Kim, Arnold H. Zea, (unknown), Samuel C. Okpechi, Dorota Wyczechowska, (unknown), Moselhy S. Mansy, Augusto C. Ochoa, Amarjit S. Naura, A. Hamid Boulares	33

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact